Exact Sciences
JPM Healthcare Conference Day 3: Quantum-Si, Olink, Exact Sciences, Bio-Techne, Opko Health, More
Highlights of the third day included Quantum-Si's plans for its protein sequencing platform and strategic initiatives from Opko's BioReference Laboratories.
Exact Sciences Projects up to $475M in Q4 Revenues, Acquires Testing Lab, Inks Licensing Deal
The approximately 2 percent increase over Q4 2020 results beat analysts' expectations, and the acquisition news heralds market expansion into hereditary cancer testing.
RxPONDER Update Yields No Clear Guidance on Chemo Decisions for Younger Breast Cancer Patients
Premium
A large, randomized trial exploring the benefit of adding chemo to endocrine therapy for premenopausal women with Oncotype DX scores of 0 to 25 will likely be needed.
Exact Sciences, Pfizer End Cologuard Copromotion Agreement
In September, Exact hired 400 former Pfizer sales reps who were displaced from their jobs in late August and who had been promoting Cologuard.
Exact Sciences, Jefferson Health to Study Blood-Based Multicancer Early Detection Test
The partners will survey doctors, care coordinators, and patients on metrics like test safety and efficacy, and how to best implement multicancer testing.